Consolidation therapy: What should be the standard of care?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 53-60

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

acute myelogenous leukemia; AML; Ara C; consolidation therapy; younger adults

Indexed keywords

AMSACRINE; CYTARABINE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSOLIDATION THERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TOLERANCE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; CYTARABINE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION;

EID: 40849098011     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.004     Document Type: Review

References (17)

1. Cassileth P.A., Lynch E., Hines J.D., et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79 (1992) 1924-1930
2. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. The New England Journal of Medicine 331 (1994) 896-903
3. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. The New England Journal of Medicine 339 (1998) 1649-1656
4. Bloomfield C.D., Lawrence D., Byrd J.C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research 58 (1998) 4173-4179
5. Byrd J.C., Dodge R.K., Carroll A., et al. Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Journal of Clinical Oncology 17 (1999) 3767-3775
6. Byrd J.C., Ruppert A.S., Mrozek K., et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t(16;16) (p13;q22): results from CALGB 8461. Journal of Clinical Oncology 22 (2004) 1087-1094
7. Moore J.O., George S.L., Dodge R.K., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105 (2005) 3420-3427
8. Elonen E., Almqvist A., Hanninen A., et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 12 (1998) 1041-1048
9. Rowe J.M. Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?. Leukemia 19 (2005) 1324-1327
10. Abou-Jawde R.M., Sobecks R., Pohlman B., et al. The role of post-remission chemotherapy for older patients with acute myelogenous leukemia. Leukemia & Lymphoma 47 (2006) 689-695
11. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1312-1320
12. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
13. Buchner T., Berdel W.E., Schoch C., et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. Journal of Clinical Oncology 24 (2006) 2480-2489
14. Goldstone A.H., Burnett A.K., Wheatley K., et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1302-1311
15. Buchner T., Hiddemann W., Berdel W.E., et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Journal of Clinical Oncology 21 (2003) 4496-4504
16. Stone R.M., Berg D.T., George S.L., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98 (2001) 548-553
17. Rowe J.M., Andersen J.W., Mazza J.J., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86 (1995) 457-462